1360 – Clinical Consequences of Delaying Implementation of LA-ART for PWH With Persistent Viremia in the US
Background Long-acting (LA-) injectable cabotegravir-rilpivirine (CAB/RPV) can achieve viral suppression (VS) in PWH with poor adherence to daily ART and persistent viremia. While current DHHS guidelines recommend this indication for CAB/RPV on a case-by-case basis, the FDA is requiring a randomized trial for approval. Our objective was to project the clinical impact of delaying CAB/RPV…